Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) EBT Margin (2022 - 2023)

Pasithea Therapeutics (KTTA) has disclosed EBT Margin for 2 consecutive years, with 1034.5% as the latest value for Q2 2023.

  • Quarterly EBT Margin rose 1508993.0% to 1034.5% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 4629.79% through Mar 2024, down 131462.0% year-over-year, with the annual reading at 2410.37% for FY2022, 1202012.0% up from the prior year.
  • EBT Margin hit 1034.5% in Q2 2023 for Pasithea Therapeutics, down from 5475.32% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 5475.32% in Q1 2023 to a low of 16124.43% in Q2 2022.